Table 3.

Incidence of Acute and Chronic GVHD in TBF Versus Treo

	180-d Grade I–IV aGVHD (95% CI)	180-d Grade III–IV aGVHD (95% CI)	2-y cGVHD, Any Grade (95% CI)	2-y cGVHD, Severe (95% CI)
TBF	29% (21-37)	12% (7-18)	32% (23-42)	13% (7-21)
Treo	20% (13-27)	10% (6-16)	41% (30-51)	12% (7-20)
HR (95% CI)	1.48 (0.96-2.3)	1.21 (0.67-2.17)	0.71 (0.44-1.12)	1.07 (0.48-2.37)
P-value	0.08	0.53	0.14	0.87

CI = confidence interval; d = days; GVHD = graft-vs-host disease; HR = hazard ratio; TBF = thiotepa, busulfan, fludarabine; Treo = treosulfan-based regimen; y = years.